These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 22095818)

  • 1. Clinical and economic analysis of short-course versus standard-course antithymocyte globulin (rabbit) induction therapy in deceased-donor renal transplant recipients.
    Marfo K; Akalin E; Wang C; Lu A
    Am J Health Syst Pharm; 2011 Dec; 68(23):2276-82. PubMed ID: 22095818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
    Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose rabbit anti-thymoglobin globulin versus basiliximab for induction therapy in kidney transplantation.
    Patel HV; Kute VB; Vanikar AV; Shah PR; Gumber MR; Engineer DP; Trivedi HL
    Saudi J Kidney Dis Transpl; 2014 Jul; 25(4):819-22. PubMed ID: 24969194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
    Martin ST; Roberts KL; Malek SK; Tullius SG; Vadivel N; De Serres S; Grafals M; Elsanjak A; Filkins BA; Chandraker A; Gabardi S
    Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Antibody-Based Induction Therapy in Deceased Donor Kidney Transplantation in the United States.
    Gharibi Z; Ayvaci MUS; Hahsler M; Giacoma T; Gaston RS; Tanriover B
    Transplantation; 2017 Jun; 101(6):1234-1241. PubMed ID: 27379555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression.
    Miller JT; Collins CD; Stuckey LJ; Luan FL; Englesbe MJ; Magee JC; Park JM
    Pharmacotherapy; 2009 Oct; 29(10):1166-74. PubMed ID: 19792990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study.
    Kim JM; Jang HR; Kwon CH; Huh WS; Kim GS; Kim SJ; Joh JW; Oh HY
    Transplant Proc; 2012 Jan; 44(1):167-70. PubMed ID: 22310606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients.
    Khanmoradi K; Knorr JP; Feyssa EL; Parsikia A; Jawa P; Dinh DB; Campos S; Zaki RF; Ortiz JA
    Exp Clin Transplant; 2013 Jun; 11(3):222-8. PubMed ID: 23432665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
    Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
    N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and economic analysis of delayed administration of antithymocyte globulin for induction therapy in kidney transplantation.
    McGillicuddy JW; Taber DJ; Pilch NA; Kohout RK; Bratton CF; Chavin KD; Baliga PK
    Prog Transplant; 2013 Mar; 23(1):33-8. PubMed ID: 23448818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of extended-duration inpatient-to-outpatient rabbit antithymocyte globulin induction in de novo kidney transplant recipients: 6-month outcomes.
    Trofe-Clark J; Reese PP; Patel HJ; Jakobowski D; Goral S; Doll SL; Abt PL; Bloom RD
    Transplantation; 2012 Sep; 94(5):506-12. PubMed ID: 22895613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
    Sollinger H; Kaplan B; Pescovitz MD; Philosophe B; Roza A; Brayman K; Somberg K
    Transplantation; 2001 Dec; 72(12):1915-9. PubMed ID: 11773888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporin after renal transplantation.
    Cantarovich D; Giral-Classe M; Hourmant M; Dantal J; Blancho G; Lerat L; Moreau A; Soulillou JP
    Nephrol Dial Transplant; 2000 Oct; 15(10):1673-6. PubMed ID: 11007839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
    Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S
    Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Cost-effectiveness Analysis of Rabbit Antithymocyte Globulin Versus Antithymocyte Globulin-fresenius as Induction Therapy for Patients With Kidney Transplantation From Donation After Cardiac Death in China.
    Xuan D; Chen G; Wang C; Yao X; Yin H; Zhang L; Xuan J; Chen L
    Clin Ther; 2018 Oct; 40(10):1741-1751. PubMed ID: 30243768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
    Ravichandran P; Natrajan T; Jaganathan R
    Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Early Steroid Withdrawal in Recipients of Deceased-Donor Expanded Criteria Kidney Transplants in the Era of Induction Therapy.
    Hussain SM; Marcus RJ; Ko TY; Nashar K; Thai NL; Sureshkumar KK
    Exp Clin Transplant; 2016 Jun; 14(3):287-93. PubMed ID: 27221720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
    Pilch NA; Taber DJ; Moussa O; Thomas B; Denmark S; Meadows HB; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD
    Ann Surg; 2014 May; 259(5):888-93. PubMed ID: 24513787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Ideal Versus Total Body Weight Dosage of Rabbit Antithymocyte Globulin on Outcomes of Kidney Transplant Patients With High Immunologic Risk.
    Vacha M; Gommer J; Rege A; Sanoff S; Sudan D; Harris M
    Exp Clin Transplant; 2016 Oct; 14(5):511-517. PubMed ID: 26742693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up.
    Laftavi MR; Alnimri M; Weber-Shrikant E; Kohli R; Said M; Patel S; Pankewycz O
    Transplant Proc; 2011 Mar; 43(2):458-61. PubMed ID: 21440733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.